Sleep Apnea and Alzheimer’s: A New Link in the Immune and Inflammatory Chain
A new study published in Alzheimer’s & Dementia reveals a significant association between the severity of obstructive sleep apnea (OSA) and key plasma biomarkers for Alzheimer’s disease (AD). Researchers examined 120 cognitively normal older adults, measuring OSA severity and analyzing plasma levels of amyloid beta peptides (Aβ40, Aβ42), tau, and neurofilament light chain (NfL). They found that increased OSA severity correlated with higher plasma levels of Aβ40, Aβ42, and the Aβ42/Aβ40 ratio. Furthermore, the relationship between OSA and plasma markers of neurodegeneration, like tau and NfL, was dependent on the presence of cerebrospinal fluid amyloidosis. Crucially, combining the measure of OSA severity with the plasma Aβ42/Aβ40 ratio improved the non-invasive detection of both brain amyloidosis and tau pathology, offering a potential new screening tool.
Study Significance: This research bridges sleep medicine and neuroimmunology, suggesting that chronic intermittent hypoxia from OSA may dysregulate innate immune pathways and inflammatory cytokine networks, potentially accelerating amyloid pathology. For immunologists, it underscores the role of systemic inflammation and peripheral immune markers in central nervous system disease. The findings highlight a practical, modifiable risk factor for AD and propose a composite biomarker strategy that could refine early detection protocols and inform future immunotherapy targets aimed at neuroinflammation.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
